# <sup>1</sup> Trends in TSH, free T4, and anti-thyroid

# <sup>2</sup> peroxidase and treatment status: Canadian

<sup>3</sup> Health Measures Survey 2012 to 2015

### 4 Authors and affiliations

- 5 1. Yi-Sheng Chao, MD MPH PhD\*
- 6 Independent researcher
- 7 Email: chaoyisheng@post.harvard.edu
- 8 \*Corresponding author
- 9
- 10 \*Corresponding author
- 11
- 12

# 13 Abstract

#### 14 Background

- 15 Previous studies in Canada focused on the prevalence of thyroid conditions have not
- 16 reported on the levels of the thyroid-stimulating hormone (TSH) and thyroid hormones. To
- 17 address this issue, the present study describes the trends in TSH, free T4, and anti-thyroid
- 18 peroxidase and their treatment status for the patients who have clinically high or low levels.

#### 19 Methods

- 20 We used data from the Canadian Health Measures Survey (CHMS) cycles 3 and 4 conducted
- 21 between 2012 and 2015. The thyroid measures studied were TSH, free T4, and anti-thyroid
- 22 peroxidase. We used clinical reference ranges to identify abnormality in these measures.
- 23 We labelled abnormality in these measures as *treated* if relevant conditions were diagnosed
- 24 or a disease-specific prescription was reported. *Untreated* individuals were those with an
- 25 abnormality in thyroid measures without any medication use or relevant diagnoses. We
- 26 presented the trends of thyroid measures in mean values and ratios, compared to the values
- 27 first measured.

#### 28 Results

- 29 The levels of TSH, free T4, and anti-peroxidase in cycle 4 were not significantly different
- 30 from those in cycle 3. The proportions of Canadians with clinically high levels of free T4,
- 31 anti-thyroid peroxidase, and TSH were 0.03 to 0.017, 0.005 to 0.005, and 0.30 to 0.43 for
- 32 cycles 3 to 4, respectively. The proportions of Canadians with clinically low levels of TSH
- and free T4 were 0.02 to 0.021 and 0.18 to 0.11 for cycles 3 to 4, respectively. The change in
- 34 the proportions of treatment statuses varied across the thyroid measures of the Canadians
- 35 studied.

#### 36 Conclusion

- 37 This descriptive study demonstrates the trends in TSH, free T4, and anti-thyroid
- 38 peroxidase; their distributions in the population; and the proportions of Canadians with
- 39 clinically high or low levels. We believe the information on the treatment status of those
- 40 with uncontrolled high levels can be used to design patient screening programs.

#### 41 Key words

- 42 Canadian Health Measures Survey (CHMS), trends, thyroid hormone, thyroid-stimulating
- 43 hormone, treatment status
- 44

## 45 Background

It was estimated that in 2008 and 2009, 10.4% of Canadians aged 45 years or older 46 47 had thyroid conditions (unspecified).[1, 2] Not all patients present symptoms and are treated.[1] However, thyroid conditions left untreated can lead to adverse cardiac 48 49 outcomes, such as hypertension and dyslipidemia.[1] Asymptomatic patients can be 50 identified through population screening. The screening of thyroid conditions often is done by measuring the levels of blood thyroid-stimulating hormone (TSH).[1] In clinics, free 51 thyroxine (T4) and anti-thyroid peroxidase are two of the thyroid measures tested to 52 53 determine a differential diagnosis of hyper- or hypothyroidism.[3] 54 Certain treatment options are available for asymptomatic thyroid conditions, such as 55 levothyroxine for screen-detected hypothyroidism.[1] However, concerns have be raised with respect to the population screening for thyroid conditions. First, levels of TSH may 56 fluctuate. For example, a 5-year cohort study found that abnormal levels of TSH in some 57 primary care patients returned to normal levels.[4] Second, no strong evidence exists to 58 59 support treatment for asymptomatic patients. A systematic review by the Canadian Task Force on Preventive Health Care found a lack of statistical significance in the differences in 60 61 mortality, weight change, and harms between the treated and untreated screen-detected 62 thyroid patients.[1] Therefore, screening the thyroid conditions of the general public is not recommended, with the exception of those individuals with previous thyroid conditions or 63 those who have received thyroid interventions.[1] Last, overdiagnosis is a concern that may 64 65 occur when a condition is detected that would not otherwise have been diagnosed in an 66 individual's lifetime.[5] Globally, in developed and developing countries, a trend in thyroid cancer overdiagnosis is increasing.[5] For example, in the Republic of Korea, a 15-fold 67 increase occurred in the diagnosis of thyroid cancer between 1993 and 2011, even though 68 69 the thyroid cancer mortality rate remained similar to the 1993 level throughout the period,[6] Thus, a trend of overdiagnosis of thyroid cancer in the Republic of Korea is 70 71 likely.[6] 72 In Canada, thyroid cancer is not targeted by cancer screening programs[7], and screening for thyroid conditions is not recommended.[1] It is unclear whether the lack of 73 74 support for screening is the reason why studies reporting the statistics on TSH and other 75 thyroid measures are few. Currently, little information is available as to whether an 76 overdiagnosis or undertreatment of thyroid conditions is occurring. Previous studies have 77 used a trend analysis of blood pressure and environmental chemicals to demonstrate their 78 distributions in the populations and to detect significant changes in the levels of biomarkers 79 over time.[8-10] The trends in, and the treatment status of, TSH and thyroid hormones may 80 be useful for understanding how thyroid conditions are clinically managed in Canada.

81 Therefore, this descriptive study conducts a trend analysis of TSH, free T4, and anti-thyroid

82 peroxidase—using the thyroid measures available in a national survey—to detect whether

significant changes in their levels are occurring in Canadians, and to estimate the treatment
 statuses of these thyroid measures.

# 85 Methods

We used data from the Canadian Health Measures Survey (CHMS) cycles 3 and 4 implemented in 2012 to 2013 and 2014 to 2015, respectively.[8-10] For each of these cycle,

- 88 more than 5,000 non-institutionalized Canadians, aged 3 to 79 years were sampled (for
- 89 details about inclusion and exclusion criteria, see previous publications).[11, 12] statistical
- 90 weights were applied to the subjects to estimate the overall distributions and levels of
- 91 selected measures for more than 30 million non-institutionalized Canadians.[13] Three
- 92 thyroid measures were available for the CHMS cycles 3 and 4: free T4 (pmol/l), anti-thyroid
- 93 peroxidase (U/ml), and TSH (mIU/l).[14]

# 94 Abnormality identification for blood measures

We assessed TSH, free T4, and anti-thyroid peroxidase for abnormality, values
higher or lower than upper or lower reference limits, respectively. The reference ranges for
TSH were 0.4 to 4.8 mIU/l for adults and 1.7 to 9.1 mIU/l for those aged 21 weeks to 20
years.[15] The reference ranges for free T4 were 13 to 27 pmol/l.[15] The upper limit of the

99 anti-thyroid peroxidase reference range was 35 U/ml.[16]

# 100 Treatment status identification

101 We defined the *treatment status* according to the use of medication and the chronic 102 condition diagnoses reported by participants.[17-20] We estimated the treatment status in 103 four categories: treated, probably treated, potentially treated, and untreated (see Table 1). 104 To avoid over-identification, we defined *untreated individuals* as those who had not 105 reported the use of any medications or any related chronic conditions defined by the CHMS 106 (any chronic conditions, cardiovascular disease, high blood pressure, abnormal lipid profile, 107 stroke, kidney disease, liver disease, thyroid disease, diabetes, cancer, eating disorder, or 108 chronic obstructive pulmonary disease). We regarded individuals as *treated* only if they 109 were diagnosed with thyroid disease or who were taking thyroid prescription drugs. 110 Individuals were *probably treated* if they were diagnosed with the above-mentioned

- chronic conditions that might affect clinical measures or were taking any prescription
  drugs. Individuals were regarded as *potentially treated* if they reported any chronic
  conditions or were taking any prescription or over-the-counter drugs.
- We reported *medication use* based on the Anatomical Therapeutic Chemical (ATC) classification system.[9, 21] *Medication* in the CHMS data was labelled as prescription, overthe-counter drugs, and health products.[9] Over-the-counter drugs and health products were regarded as *non-prescription*.[9] We extracted the ATC codes that represented prescription or over-the-counter drugs from the medication file of each cycle. In Table 1,
- the first and second levels of the ATC codes that represented thyroid medications were indicated as "G03."

# 121 Data analysis

- 122 We conducted a trend analysis using all the variables available from the CHMS.[8, 9, 123 22] First, we summarized these variables using basic characteristics, such as maximal and minimal values, and we linked the survey and bootstrap weights to them.[22] Then, we 124 125 identified the missing values and the values beyond the detection levels for all the 126 variables.[10] We recorded basic statistics, such as the weighted mean, and the 25th and 127 75th percentiles.[10] We introduced clinical reference ranges to identify Canadians with 128 abnormal levels of thyroid measures. We labelled four treatment statuses based on chronic 129 conditions and medication use. We used the CHMS cycles as the proxy measure for time
- 130 points in our trend analysis. Using ratios, we compared the distributions of TSH, free T4,

and anti-thyroid peroxidase in CHMS cycle 2 (2012 to 2013) to their distributions in CHMS

132 cycle 3 (2014 to 2015).[9, 10, 23] We described the trends with ratios with 95% confidence

- 133 intervals (CIs). The 95% CIs of the ratios in the subsequent cycles covering 1 indicated
- insignificant changes in the levels of thyroid measures after cycle 3. We conducted the data
- 135 analysis with R (v3.20)[24] and RStudio (v0.98.113).[25]

# 136 **Results**

- 137 The population characteristics in the same period were published.[9, 10] In
- 138 summary, throughout the CHMS cycles 3 to 4, around 30 million Canadians were estimated
- and almost half of them were female.[9, 10] The mean ages of the two cycles were 39.00
- and 39.30 years.[8-10] The trends of free T4, anti-peroxidase, and TSH of cycles 3 and 4 are
   represented in Tables 2, 3, and 4. The levels of free T4 were all within the detection limits.
- 142 The proportions of individuals reaching the lower detection limits were 0.39, 0.30, and less
- 143 than 0.0002 for anti-thyroid peroxidase in cycles 3 and 4 and TSH in cycle 3, respectively.
- 144 Since the lower reference range for anti-thyroid peroxidase was not defined, and the
- 145 proportion of TSH lower than the detection levels was small, the proportions of thyroid
- 146 measures lower than the detection levels did not influence the subsequent analysis. Based
- 147 on the ratios in cycle 4, the levels of TSH, free T4, and anti-thyroid peroxidase were not
- 148 significantly different from those levels in cycle 3 (ratio 95% CIs covering 1 for all).

# 149 **Proportions of abnormality in blood measures**

- 150 The proportions of Canadians with levels higher or lower than the reference ranges 151 differed for TSH, free T4, and anti-thyroid peroxidase. There was an increase in the 152 proportions of Canadians with high levels of anti-thyroid peroxidase and low levels of TSH. 153 There was a decrease in the proportions of Canadians with high levels of free T4 and TSH, 154 and low levels of free T4. The proportions of Canadians with clinically high levels of free T4, anti-thyroid peroxidase, and TSH were 0.005 to 0.005, 0.30 to 0.43, and 0.03 to 0.017 for 155 156 cycles 3 to 4, respectively. The proportions of Canadians with clinically low levels of free T4 157 and TSH were 0.18 to 0.11 and 0.02 to 0.021 for cycles 3 to 4, respectively. The lower 158 reference limit for anti-thyroid peroxidase was not defined, and the proportion with 159 clinically low levels was not available.
- 160 Treatment status for clinically high levels
- 161 The four estimated treatment status varied for TSH, free T4, and anti-thyroid 162 peroxidase. Due to an insufficient number of unweighted sample sizes, the proportions of 163 Canadians being treated with high levels of free T4 were not reported in Table 2. The 164 proportions of Canadians who were untreated—based on drug use and self-reported 165 conditions—were all less than 5% of Canadians with high levels of free T4, anti-thyroid 166 peroxidase, and TSH: 0 to 0.009, 0.02 to 0.03, and 0.01 to 0.049 for cycle 3 and 4, 167 respectively.
- The proportions of Canadians treated with high levels of TSH and anti-thyroid
  peroxidase were 0.31 to 0.44 and 0.15 to 0.11 for cycles 3 to 4, respectively; whereas
  sufficient sample sizes were unavailable for estimating this proportion for free T4.
  The present study uniquely identified two treatment statuses—*probably treated* or *potentially treated*. Among those with high levels of free T4, anti-thyroid peroxidase, and

- 173 TSH, the proportions of being probably treated were high: 0.34 to 0.92, 0.90 to 0.90, and
- 174 0.87 to 0.86 for cycles 3 to 4, respectively. Among Canadians with high levels of free T4,
- 175 anti-thyroid peroxidase, and TSH, the proportions of being probably treated were high: 1 to
- 176 0.99, 0.98 to 0.97, and 0.99 to 0.95 for cycles 3 to 4, respectively.

### 177 Treatment status for clinically low levels

- 178 The treatment status for clinically low levels of anti-thyroid peroxidase was not 179 defined. The proportions of Canadians with low levels of free T4 and TSH were 0.18 to 0.11
- and 0.020 to 0.021 for cycles 3 to 4, respectively. The proportions of *untreated* Canadians
- 181 with low levels of free T4 and TSH were 0.025 to 0.007 and 0 to 0.01 for cycles 3 to 4,
- respectively. The proportions of Canadians being *treated* who had low levels of free T4 and TSH were 0.09 to 0.04 and 0.44 to 0.41 for cycles 3 to 4, respectively.
- 183 TSH were 0.09 to 0.04 and 0.44 to 0.41 for cycles 3 to 4, respectively.
- 184 The proportions of Canadians being *probably treated* were high for free T4 and TSH.
- 185Thus, the proportions of Canadians with low levels of free T4 and TSH being probably
- 186 treated were 0.89 to 0.93 and 0.87 to 0.91 for cycles 3 to 4, respectively. The proportions of
- 187 Canadians being *potentially treated* were almost 1 for free T4 and TSH. Thus, the
- 188 proportions of Canadians with low levels of free T4 and TSH being potentially treated were
- 189 0.97 to 0.99 and 1 to 0.99 for cycles 3 to 4, respectively.

# 190 **Discussion**

Surprisingly, based on our findings, little attention has been paid to the trends in
thyroid measures, their distributions in the population, and the clinically low levels of
thyroid measures. Building on previous studies, [26] we did not limit the scope of our study
to subjects with clinically high levels.

The levels of TSH, free T4, and anti-thyroid peroxidase were stable throughout CHMS cycles 3 to 4. According to the CHMS surveys, Canadians have high proportions of abnormal (high or low) levels of anti-thyroid peroxidase and free T4 (more than 11%). The proportions of Canadians with abnormal levels of TSH, a screening target, were 5% or less. Also, the proportions of Canadians with high levels of anti-thyroid peroxidase and low

- levels of TSH may have increased, and the proportions of Canadians with high levels of free
  T4 and TSH and low levels of free T4 may have decreased.
- High proportions of Canadians with abnormal levels of TSH, free T4, and anti-thyroid peroxidase were probably treated, taking any prescriptions, or diagnosed with thyroid disease or other chronic conditions, which may suggest a high health care coverage for Canadians with abnormal levels of TSH, free T4, and anti-thyroid peroxidase.
- A previous study using CHMS cycle 3 data with the same population and a slightly different reference range (0.55 to 4.78 mIU/l, compared to 0.4 to 4.8 mIU/l of the present study) found that the proportions of Canadians with clinically high, normal, and low levels of TSH in cycle 3 were 3.33%, 93.15%, and 3.52%, respectively, compared to 3.04%, 94.98%, and 1.98% of the present study.[27] The similarity of these estimates suggests that the analysis of the present study is accurate.
- Since Canada lacks a comprehensive reporting of thyroid conditions, the prevalence of thyroid conditions in Canada is based on sporadic reports. Between 2008 and 2009, the prevalence of thyroid conditions in the Canadian population was 10.4% among those aged
- 215 45 years and over.[2] The estimated prevalence of thyroid condition was 5.67% and 6.85%

among Canadians aged 3 and over in 2009 to 2011 and 2012 to 2013, respectively.[27] In

217 the US, the prevalence of thyroid conditions was estimated to be 16.18% in women and

218 3.06% in men, reported by participants interviewed between 1999 and 2006.[28] This

study and others have shown that some of the patients with abnormal levels of TSH remain

undiagnosed.[28, 29]

#### 221 Treatment and clinically abnormal levels

222 One feature of the present study is its four treatment statuses indicating the intensity 223 of medical interventions that Canadians have received. Moreover, the proportions of the four treatment statuses that identified TSH, free T4, and anti-thyroid peroxidase were 224 225 different. The first finding based on treatment statuses is that thyroid medications are 226 rarely used by Canadians with high levels of free T4. An increase in the levels of free T4 has 227 been linked to increased risks of developing any solid cancer, lung cancer, and breast cancer, regardless of the TSH levels.[30] This outcome may be due to the activation of 228 229 ontogenetic pathways and tumor-growth-related genes.[30] The second finding is that the majority of Canadians with abnormal levels of TSH, free T4, or anti-thyroid peroxidase were 230 231 probably treated (were taking prescriptions or diagnosed with chronic conditions), more 232 than 86%, except free T4 in cycle 3 (34%). Whether this is due to an increase in the 233 treatment coverage, changes to clinical practice, or differences in sampling methods needs 234 to be confirmed with future CHMS cycles.

235 The third finding based on treatment statuses is that although individuals may be 236 treated, the levels of thyroid measures remain abnormal, i.e., inadequately controlled. The 237 proportions of individuals with inadequately controlled levels of lipid profile in the general public have been used to assess the performance of health care systems.[18] TSH, free T4, 238 239 and total T3 are important measures to follow-up with patients who have a thyroid 240 condition.[31, 32] Our estimates of the proportions of uncontrolled high or low levels of 241 TSH are more than 31% or 40% among those with high or low levels of TSH, respectively. 242 The proportions of uncontrolled high or low levels of free T4 are less than 1% or more than 243 4% among those with high or low levels of free T4, respectively. We did not find similar 244 statistics reported by other researchers. Whether these present study statistics are useful 245 for assessing the efficacy of thyroid condition intervention remains to be investigated.

246 The fourth finding based on treatment statuses is that the association of medical 247 interventions with the proportions of clinically high or low levels of TSH, free T4, and anti-248 thyroid peroxidase varies. Various factors can modify treatment efficacy, such as intervention duration, treatment doses, frequency, [33], and compliance to medical 249 250 interventions.[20, 34, 35] It remains unclear whether the proportions of inadequately controlled abnormality of thyroid measures is a useful indicator for assessing intervention 251 252 adequacy for those patients with abnormal levels of TSH, free T4, or anti-thyroid 253 peroxidase.

Last, opportunities may exist to intervene based on the association of treatment statuses and abnormality in blood measures. The differences in the proportions of *being treated* and *potentially treated* among Canadians with clinically high or low levels are more than 50% for TSH, free T4, and anti-thyroid peroxidase in cycles 3 and 4. The difference between being probably treated and potentially treated is taking over-the-counter medications, which suggests that most Canadians with abnormal levels of TSH, free T4, or anti-thyroid peroxidase were taking some medication. With respect to TSH, this suggests

- that more than 94% of Canadians with clinically high or low levels may be targeted for
- 262 interventions through their regular access to medication. Several pharmacist-led initiatives
- 263 have been designed to screen conditions for treatment, for example, sexually transmitted
- infections,[36] sleep apnea,[37] asthma, obesity, and hypertension.[38] Also, pediatric
- 265 patients have been identified by pharmacist-led screening programs.[38] Our results may
- 266 help to refine the directions and magnitudes that health authorities can use to design
- 267 population screening programs when necessary.
- 268 **Overdiagnosis of thyroid conditions?**
- 269 Korean researchers used a 15-fold increase in thyroid cancer diagnosis prevalence 270 and stable thyroid cancer mortality to demonstrate the possible extent of overdiagnosis of 271 thyroid cancer.[6] The present study was not designed to directly assess an overdiagnosis 272 or undertreatment of a thyroid condition, but the trends in, and the treatment statuses of, 273 thyroid measures can be used as the foundation for assessing these issues. Thus, the 274 present study findings can be informative for planning an investigation of the overdiagnosis 275 or undertreatment of thyroid conditions. First, it may not be adequate to assess the trends 276 in thyroid treatment solely based on the use of a thyroid prescription (ATC codes beginning with G03) because the use rate is low among those with abnormal levels of TSH. Second, the 277 278 levels of TSH, free T4, and anti-thyroid peroxidase remain similar throughout the CHMS 279 cycles 3 and 4. These trends provide important baseline data for future monitoring. 280 Whether the trends in TSH, free T4, and anti-thyroid peroxidase may be changed or altered 281 by other factors can be studied with such data.
- Last, the assessment of overdiagnosis is difficult with information based only on blood measures and treatment status at two time points. A long-term follow-up and major health outcomes, such as mortality, will be needed for assessing an overdiagnosis.[6] At the same time, the measures of the CHMS are subject to changes in medical practices and sampling frames, or to measurement errors.[8] Without obvious signs in CHMS cycles 3 and 4, this issue needs to be monitored in the future.

### 288 Sick population versus sick individuals

289 The results of the present study show that large proportions of Canadians with 290 clinically high or low levels of anti-thyroid peroxidase and free T4 may highlight the 291 shortcomings of current health care that focus more on sick individuals than the signs of 292 increasing risks to thyroid health in the general population.[39] Previous Canadian studies 293 have reported on only the proportions of patients with clinically high or low levels of 294 TSH.[27] With respect to the Canadian population, the distributions of TSH, free T4, and 295 anti-thyroid peroxidase have not been well studied, let alone the trends of their 296 distributions. Our research group has been developing tools to analyze trends in national 297 surveys[8-10] and to demonstrate the importance of trends in blood measures and 298 environmental chemicals.[8-10] If the increasing risks of thyroid conditions are limited only 299 to certain subgroups, preventive strategies should monitor and focus on individuals with 300 such characteristics, i.e., the high-risk strategies described by Geoffrey Rose.[39] However, 301 the increase in risks applies to the general population. This strategy will require policies 302 that do not focus on certain individuals, i.e., the population strategies described by Geoffrey 303 Rose.[39] We think the results of this trend analysis provide a good foundation for a

discussion on how to reduce the risk for Canadians to develop long-term consequences ofuntreated or undertreated thyroid conditions.

#### 306 Limitations

307 Fluctuations of large magnitudes in other blood measures or environmental 308 chemicals have occurred throughout CHMS cycles 1 to 4.[8] Besides the changes in the 309 distributions of blood measures across time, other factors may lead to different levels of 310 blood measures or various proportions of treatment statuses over time, such as differences 311 in sampling frames, quantification methods, or precisions; and changes in detection 312 levels.[8] Moreover, a lack of overall significant trends in population levels may not mean a 313 lack of significant changes in blood measure levels among subpopulations. The CHMS data 314 are not designed to track or follow-up with individuals with specific characteristics or 315 smaller geographic areas [11-13], and so it may not be adequate to conclude that significant 316 trends in all subpopulations are lacking.

# 317 Conclusion

318 Based on our findings, little attention has been paid to trends in TSH, free T4, and 319 anti-thyroid peroxidase; their distributions in the population; and clinically low levels of 320 these measures. Based on the ratios from cycles 3 to 4, significant changes are lacking in the 321 levels of TSH, free T4, and anti-thyroid peroxidase. There are more than 30% and 11% of 322 Canadians with clinically high or low levels (undetected or uncontrolled by medication) of 323 anti-thyroid peroxidase and free T4, respectively. The proportions of the four treatment 324 statuses, which represent the different treatment intensities that patients may have 325 received, are different for TSH, free T4, and anti-thyroid peroxidase. Our results show that 326 the large proportions of Canadians with clinically high or low levels of TSH, free T4, or anti-327 thyroid peroxidase may highlight the shortcomings of current health care that focus more 328 on sick individuals than the signs of increasing risks to the thyroid health of the general 329 population. We plan to research strategies to screen undiagnosed patients, and the 330 potential causes of the high proportions of uncontrolled thyroid measures.

# 331 **Declaration**

#### **332** Required statement for the analysis of Statistics Canada data at the Research Data

333 Centre

334 The analysis presented in this paper was conducted at the Quebec Interuniversity 335 Centre for Social Statistics, which is part of the Canadian Research Data Centre Network 336 (CRDCN). The services and activities provided by the QICSS were made possible by the 337 financial or in-kind support of the Social Sciences and Humanities Research Council 338 (SSHRC), the Canadian Institutes of Health Research (CIHR), the Canada Foundation for 339 Innovation (CFI), Statistics Canada, the Fonds de recherche du Québec - Société et culture 340 (FRQSC), the Fonds de recherche du Québec - Santé (FRQS) and the Quebec universities. 341 The views expressed in this paper are those of the authors, and not necessarily those of the

342 CRDCN or its partners[40].

#### 343 Ethics review

The CHMS was approved by the Statistics Canada ethics committee. The informed consent was obtained from all participants or, if participants are under 18, from a parent and/or legal guardian.[11, 12] This secondary data analysis was approved by the ethics

347 review committee at the Centre Hospitalier de l'Université de Montréal.

- 348 Acknowledgements
- 349 Not applicable.

#### 350 Funding

351 No specific funding was received for this project.

#### 352 Conflict of interests

YSC is employed by the Canadian Agency for Drugs and Technologies in Health. YSC
 conducted this study as an independent researcher out of academic curiosity without
 external support.

- 356 Author contribution
- 357 YSC conceptualized and designed this study, managed and analyzed data, and358 drafted the manuscript.

#### 359 Data Availability

360 The CHMS data are not publicly available. It is against the Statistics Act of Canada to

- release the CHMS data. The collection of the CHMS data has been approved by the ethics
- 362 committee within the governments of Canada. The CHMS data have been de-identified and
- 363 maintained by Statistics Canada. The data can be accessed through the Research Data
- Centres administered by Statistics Canada. The details and eligibility in obtaining data
- access can be found online (https://www.statcan.gc.ca/eng/rdc/process).

#### 366 **Regulations**

- 367 All methods were carried out in accordance with relevant guidelines and regulations.
- 368

# 369 **References**

3	7	0
J	'	v

370		
371	1.	Birtwhistle, R., et al., Recommendation on screening adults for asymptomatic thyroid
372		dysfunction in primary care. CMAJ, 2019. <b>191</b> (46): p. E1274-E1280.
373	2.	Statistics Canada, Table: 13-10-0466-01 (formerly CANSIM 105-1200). 2020, Statistics
374		Canada: Ottawa, ON.
375	3.	Sabatine, M.S., Pocket Medicine: The Massachusetts General Hospital Handbook of
376		Internal Medicine. 6 ed. Pocket Notebook Series. 2017: Wolters Kluwer Health.
377	4.	Meyerovitch, J., et al., Serum Thyrotropin Measurements in the Community: Five-Year
378		Follow-up in a Large Network of Primary Care Physicians. Archives of Internal
379		Medicine, 2007. <b>167</b> (14): p. 1533-1538.
380	5.	Li, M., L. Dal Maso, and S. Vaccarella, Global trends in thyroid cancer incidence and the
381		<i>impact of overdiagnosis.</i> The Lancet Diabetes & Endocrinology, 2020. <b>8</b> (6): p. 468-
382		470.
383	6.	Ahn, H.S., H.J. Kim, and H.G. Welch, Korea's Thyroid-Cancer "Epidemic" — Screening
384		and Overdiagnosis. New England Journal of Medicine, 2014. <b>371</b> (19): p. 1765-1767.
385	7.	Statistics Canada, Cancer Screening, 2017. 2018, Statistics Canada: Ottawa, ON.
386	8.	Chao, YS., et al., Opportunities and challenges from leading trends in a biomonitoring
387		project: Canadian Health Measures Survey 2007 to 2017. Frontiers in Public Health,
388		2020. <b>8</b> : p. 460.
389	9.	Chao, YS., et al., Drug trends among non-institutionalized Canadians and the impact
390		of data collection changes in the Canadian Health Measures Survey 2007 to 2015. PloS
391		one, 2019. <b>14</b> (4): p. e0214718-e0214718.
392	10.	Chao, YS., et al., Trend analysis for national surveys: Application to all variables from
393		the Canadian Health Measures Survey cycle 1 to 4. PLOS ONE, 2018. 13(8): p.
394		e0200127.
395	11.	Tremblay, M.S. and S. Connor Gorber, <i>Canadian health measures survey: brief</i>
396		<i>overview.</i> Can J Public Health, 2007. <b>98</b> (6): p. 453-6.
397	12.	Giroux, S., Canadian Health Measures Survey: sampling strategy overview. Health
398		reports / Statistics Canada, Canadian Centre for Health Information = Rapports sur
399		la sante / Statistique Canada, Centre canadien d'information sur la sante, 2007. 18
400		Suppl: p. 31-36.
401	13.	Haines, D.A., et al., An overview of human biomonitoring of environmental chemicals in
402		the Canadian Health Measures Survey: 2007–2019. International Journal of Hygiene
403		and Environmental Health, 2017. <b>220</b> (2, Part A): p. 13-28.
404	14.	Statistics Canada, Canadian Health Measures Survey (CHMS) Content summary for
405		cycles 1 to 8 Statistics Canada, Editor. 2015, Statistics Canada,: Ottawa, ON.
406	15.	Royal College of Physicians and Surgeons of Canada, <i>Clinical laboratory tests -</i>
407		Reference values, C.I.tR. values, Editor., Royal College of Physicians and Surgeons of
408		Canada,: Ottawa, ON.
409	16.	Longo, D., et al., Harrison's Principles of Internal Medicine, 18th Edition. 2011:
410		McGraw-Hill Education.
411	17.	Padwal, R.S., et al., Epidemiology of Hypertension in Canada: An Update. Canadian
412		Journal of Cardiology, 2016. <b>32</b> (5): p. 687-694.

413	18.	Joffres, M., et al., Dyslipidemia prevalence, treatment, control, and awareness in the
414		Canadian Health Measures Survey. Can J Public Health, 2013. 104(3): p. e252-7.
415	19.	McAlister, F.A., et al., Changes in the rates of awareness, treatment and control of
416		hypertension in Canada over the past two decades. Cmaj, 2011. <b>183</b> (9): p. 1007-13.
417	20.	Cutler, J.A., et al., Trends in hypertension prevalence, awareness, treatment, and
418		control rates in United States adults between 1988–1994 and 1999–2004.
419		Hypertension, 2008. <b>52</b> (5): p. 818-827.
420	21.	World Health Organization, Anatomical Therapeutic Chemical (ATC) Classification
421		System. 2013. 2013.
422	22.	Chao, YS., et al., Trend analysis for national surveys: application to all variables from
423		the Canadian Health Measures Survey cycle 1 to 4. PLoS ONE, 2018. (accepted).
424	23.	Lumley, T. and M.T. Lumley, <i>The survey package</i> . hospital, 2007. <b>24</b> : p. 1.
425	24.	R Development Core Team, R: A language and environment for statistical computing.
426	- 11	2016, R Foundation for Statistical Computing: Vienna, Austria.
427	25.	RStudio Team, RStudio: Integrated Development for R. 2016, RStudio, Inc.: Boston,
428	201	MA.
429	26.	Williams, I., et al., <i>Aetiology of hyperthyroidism in Canada and Wales</i> . Journal of
430	20.	Epidemiology & Community Health, 1983. <b>37</b> (3): p. 245-248.
431	27.	Barberio, A.M., et al., <i>Fluoride exposure and indicators of thyroid functioning in the</i>
432	27.	Canadian population: implications for community water fluoridation. J Epidemiol
433		Community Health, 2017. <b>71</b> (10): p. 1019-1025.
434	28.	Melzer, D., et al., Association between Serum Perfluorooctanoic Acid (PFOA) and
435	20.	Thyroid Disease in the U.S. National Health and Nutrition Examination Survey.
436		Environmental Health Perspectives, 2010. <b>118</b> (5): p. 686-692.
437	29.	Vanderpump, M.P.J., <i>The epidemiology of thyroid disease</i> . British medical bulletin,
438	2).	2011. <b>99</b> (1).
439	30.	Khan, S.R., et al., <i>Thyroid function and cancer risk: the Rotterdam study</i> . The Journal of
440	50.	Clinical Endocrinology & Metabolism, 2016. <b>101</b> (12): p. 5030-5036.
441	31.	Harada, T., et al., Follow-up evaluation of thyroid function after thyroidectomy for
442	51.	thyrotoxicosis. World Journal of Surgery, 1984. <b>8</b> (4): p. 436-443.
443	32.	Ross, D.S., et al., 2016 American Thyroid Association guidelines for diagnosis and
444	52.	management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid, 2016.
445		<b>26</b> (10): p. 1343-1421.
446	33.	Chao, Y.S., et al., The importance of dose, frequency and duration of vitamin d
447	55.	supplementation for plasma 25-hydroxyvitamin d. Nutrients, 2013. 5(10): p. 4067-78.
448	34.	Ostchega, Y., et al., Trends in Hypertension Prevalence, Awareness, Treatment, and
449	54.	Control in Older U.S. Adults: Data from the National Health and Nutrition Examination
450		Survey 1988 to 2004. Journal of the American Geriatrics Society, 2007. 55(7): p.
450 451		1056-1065.
451	35.	Gu, D., et al., Prevalence, Awareness, Treatment, and Control of Hypertension in China.
452	55.	Hypertension, 2002. <b>40</b> (6): p. 920.
455 454	36.	
454 455	50.	Wood, H. and S. Gudka, <i>Pharmacist-led screening in sexually transmitted infections:</i> current perspectives. Integrated pharmacy research & practice, 2018. <b>7</b> : p. 67.
455 456	37.	Perraudin, C., The effectiveness of a community pharmacist-led intervention to
	57.	
457 458		<i>improve screening for sleep apnea in primary care–A cohort study.</i> Sleep Medicine,
400		2013. <b>14</b> : p. e230.

459 460 461	38.	Elliott, J.P., et al., <i>Pharmacist-led screening program for an inner-city pediatric population.</i> Journal of the American Pharmacists Association, 2015. <b>55</b> (4): p. 413-418.
462	39.	Rose, G., Sick individuals and sick populations. International Journal of Epidemiology,
463		2001. <b>30</b> (3): p. 427-432.
464	40.	The Quebec Inter-University Centre for Social Statistics (CIQSS). Statistics Canada
465		Data. 2017 [cited 2017 Feb 1]; Available from: <u>https://www.ciqss.org/en/statistics-</u>
466		<u>canada-data</u> .
467		
468		
469		

- 471 472 Table 1. The conditions and medications used to define the treatment status of TSH, free T4, and anti-thyroid
- peroxidase in the Canadian Health Measures Survey, cycles 3 to 4 implemented in 2012 to 2013 and 2014 to 2015, 473 respectively.

Disease categories	CHMS variables	CHMS concept	Medication	ATC codes	CHMS variables	CHMS concepts	Units
Thyroid condition	ccc_82	Has a thyroid condition	Thyroid	First and second level: G03	lab_ft4	Free thyroxine	pmol/l
					lab_tsh	Thyroid stimulating hormone (TSH) or thyrotropin	pmol/l
					lab_tpo	Anti-thyroid peroxidase	∣U/m∣

- ATC = Anatomical Therapeutic Chemical; CHMS = Canadian Health Measures Survey; TSH = 474
- thyroid stimulating hormone. There are five levels in the ATC classification. The first level is 475
- represented by the first character of the codes. The second levels are the two digits 476
- 477 following the first character.

478

479

480

# Table 2. Trends in the Levels of Free T4 (thyroxine, pmol/l) and the Treatment Statuses in the Canadian Health Measures Survey Cycles 3 and 4.

	Cycle 3 (2012 to 2013)	Cycle 4 (2014 to 2015)	Change in percentage points from Cycle 3 to 4
			Mean (95% Cls, when available)
Relative changes (cycle 1 or first cycle = 1)	1 (1 to 1)	1.05 (0.94 to 1.16)	
Weighted mean	14.7 (14.35 to 15.05)	15.31 (14.92 to 15.7)	
Proportions with values lower than detection levels (%)	0	0	
Proportions with values higher than detection levels (%)	0	0	
Weighted mean	14.7 (14.35 to 15.05)	15.31 (14.92 to 15.7)	
Clinically high (%)	0.55	0.45	-0.1
Untreated among clinically high (%)	0 (0 to 0)	0.94 (-1.12 to 3)	
Untreated (%)	0 (0 to 0)	0 (0 to 0)	0
Treated among clinically high (%)	Insufficient sample sizes	Insufficient sample sizes	
Treated (%)	Insufficient sample sizes	Insufficient sample sizes	
Probably treated among clinically high (%)	33.93 (-1.9 to 69.76)	91.78 (80.61 to 102.95)	
Probably treated (%)	0.19 (-0.01 to 0.39)	0.41 (0.35 to 0.47)	0.22
Potentially treated among clinically high (%)	100 (100 to 100)	99.06 (97 to 101.12)	
Potentially treated (%)	0.55 (0.55 to 0.55)	0.45 (0.45 to 0.45)	-0.1
Clinically low (%)	17.75	11	-6.75
Untreated among clinically low (%)	2.52 (-2.42 to 7.46)	0.74 (0.21 to 1.27)	
Untreated (%)	0.45 (-0.43 to 1.33)	0.08 (0.02 to 0.14)	-0.27
Treated among clinically low (%)	8.83 (1.07 to 16.59)	4.17 (1.86 to 6.48)	
Treated (%)	1.57 (0.2 to 2.94)	0.46 (0.21 to 0.71)	-1.11
Probably treated among clinically low (%)	88.83 (85.05 to 92.61)	92.97 (90.54 to 95.4)	
Probably treated (%)	15.77 (15.1 to 16.44)	10.22 (9.95 to 10.49)	-5.55
Potentially treated among clinically low (%)	97.48 (95.66 to 99.3)	99.26 (98.73 to 99.79)	
Potentially treated (%)	17.31 (16.98 to 17.64)	10.92 (10.86 to 10.98)	-6.39

# 

#### 489 Table 3. Trends in the Levels of Anti-thyroid Peroxidase (U/ml) and the Treatment Statuses in the Canadian

490 Health Measures Survey Cycles 3 and 4.

	Cycle 3 (2012 to 2013)	Cycle 4 (2014 to 2015)	Change in percentage points from Cycle 3 to 4
			Mean (95% Cls, when available
Relative changes (cycle 1 or first cycle = 1)	1 (1 to 1)	1.13 (0.68 to 1.58)	
Weighted mean	155.03 (114.72 to 195.34)	170.53 (120.61 to 220.46)	
Proportions with values lower than detection levels (%)	38.62	29.69	
Proportions with values higher than detection levels (%)	0	0	
Weighted mean	155.03 (114.72 to 195.34)	170.53 (120.61 to 220.46)	
Clinically high (%)	30.16	43.22	13.0
Untreated among clinically high (%)	2.05 (0.74 to 3.36)	3.15 (1.33 to 4.97)	
Untreated (%)	0.62 (0.23 to 1.01)	1.36 (0.58 to 2.14)	0.7
Treated among clinically high (%)	14.53 (9.77 to 19.29)	11.41 (9.04 to 13.78)	
Treated (%)	4.38 (2.95 to 5.81)	4.93 (3.91 to 5.95)	0.5
Probably treated among clinically high (%)	90.34 (88.48 to 92.2)	89.81 (87.85 to 91.77)	
Probably treated (%)	27.25 (26.68 to 27.82)	38.82 (37.98 to 39.66)	11.5
Potentially treated among clinically high (%)	97.95 (96.64 to 99.26)	96.85 (95.03 to 98.67)	
Potentially treated (%)	29.55 (29.16 to 29.94)	41.86 (41.08 to 42.64)	12.3
Clinically low (%)			
Untreated among clinically low (%)	Not defined	Not defined	
Untreated (%)	Not defined	Not defined	
Treated among clinically low (%)	Not defined	Not defined	
Treated (%)	Not defined	Not defined	
Probably treated among clinically low (%)	Not defined	Not defined	
Probably treated (%)	Not defined	Not defined	
Potentially treated among clinically low (%)	Not defined	Not defined	
Potentially treated (%)	Not defined	Not defined	

491 CI = confidence interval.

492

493

#### 495 Table 4. Trends in the Levels of Thyroid Stimulating Hormone (mIU/l) and the Treatment Statuses in the

Canadian Health Measures Survey Cycles 3 and 4.

	Cycle 3 (2012 to 2013)	Cycle 4 (2014 to 2015)	Change in percentage points from Cycle 3 to 4
			Mean (95% Cls, when available
Relative changes (cycle 1 or first cycle = 1)	1 (1 to 1)	0.57 (0.11 to 1.03)	
Weighted mean	3.27 (0.81 to 5.74)	1.88 (1.66 to 2.1)	
Proportions with values lower than detection levels (%)	0.02	0	
Proportions with values higher than detection levels (%)	0	0	
Weighted mean	3.27 (0.81 to 5.74)	1.88 (1.66 to 2.1)	
Clinically high (%)	3.04	1.69	-1.3
Untreated among clinically high (%)	1.28 (-1.52 to 4.08)	4.89 (-1.26 to 11.04)	
Untreated (%)	0.04 (-0.04 to 0.12)	0.08 (-0.02 to 0.18)	0.0
Treated among clinically high (%)	31.19 (15.1 to 47.28)	44.07 (25.1 to 63.04)	
Treated (%)	0.95 (0.46 to 1.44)	0.74 (0.43 to 1.05)	-0.2
Probably treated among clinically high (%)	86.61 (78.99 to 94.23)	86.12 (76.26 to 95.98)	
Probably treated (%)	2.63 (2.39 to 2.87)	1.46 (1.3 to 1.62)	-1.1
Potentially treated among clinically high (%)	98.72 (95.92 to 101.52)	95.11 (88.96 to 101.26)	
Potentially treated (%)	3 (2.92 to 3.08)	1.61 (1.51 to 1.71)	-1.3
Clinically low (%)	1.98	2.1	0.1
Untreated among clinically low (%)	0 (0 to 0)	1.02 (-0.98 to 3.02)	
Untreated (%)	0 (0 to 0)	0.02 (-0.02 to 0.06)	0.0
Treated among clinically low (%)	43.89 (16.69 to 71.09)	40.64 (26.49 to 54.79)	
Treated (%)	0.87 (0.32 to 1.42)	0.85 (0.56 to 1.14)	-0.0
Probably treated among clinically low (%)	87.2 (68.27 to 106.13)	90.64 (76.63 to 104.65)	
Probably treated (%)	1.73 (1.36 to 2.1)	1.9 (1.61 to 2.19)	0.1
Potentially treated among clinically low (%)	100 (100 to 100)	98.98 (97.49 to 100.47)	
Potentially treated (%)	1.98 (1.98 to 1.98)	2.08 (2.04 to 2.12)	0.1

#### CI = confidence interval.